Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
-
ETF
Equity
- years
198 holdings
$67.53
Price+1.28%
$0.86
$24.953m
Small
$1.935k
Avg Volume$20.885m
$60.11
NAV0.79%
Expense Ratio0.00%
Yield$0.00
Dividend